Advanced Proteome Therapeutics Corporation
APCH.V
TSX
| 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.82% | 56.64% | 172.38% | -90.70% | -63.58% |
| Depreciation & Amortization | -- | 0.00% | 0.00% | -190.91% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.22% | 7.37% | 27.31% | 55.10% | 25.80% |
| Operating Income | 39.22% | -7.37% | -27.31% | -55.10% | -25.80% |
| Income Before Tax | -194.99% | -156.98% | -140.40% | -186.69% | 69.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -194.99% | -156.98% | -140.40% | -186.69% | 69.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -41.65% | 25.40% | 35.18% | 162.82% | 69.26% |
| Net Income | -215.93% | -144.28% | -131.03% | -150.53% | 72.00% |
| EBIT | 39.22% | -7.37% | -27.31% | -55.10% | -25.80% |
| EBITDA | 38.94% | -7.33% | -27.41% | -55.56% | -25.49% |
| EPS Basic | -207.63% | -142.33% | -129.61% | -147.50% | 78.39% |
| Normalized Basic EPS | 77.14% | -132.08% | -124.35% | -147.06% | 79.35% |
| EPS Diluted | -207.63% | -142.33% | -129.61% | -147.50% | 78.39% |
| Normalized Diluted EPS | 77.14% | -132.08% | -124.35% | -147.06% | 79.35% |
| Average Basic Shares Outstanding | 2.60% | 4.67% | 5.10% | 5.17% | 29.77% |
| Average Diluted Shares Outstanding | 2.60% | 4.67% | 5.10% | 5.17% | 29.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |